SLCO1B3 and cancer: Given that mitochondrial FAO and OXPHOS have been considered as druggable targets for cancer treatment [42, 43], Ct-OATP1B3 might be a new choice that can be used to interfere with these pathways with high specificity because of its predominant or exclusive expression in many kinds of cancer cells.